Altaris Strikes $375M Deal to Acquire Simulations Plus
Private equity firm Altaris is set to acquire pharmaceutical modeling software maker Simulations Plus in a $375 million transaction.
Private equity firm Altaris has agreed to acquire Simulations Plus, a maker of simulation and modeling software widely used in pharmaceutical drug development, in a deal valued at approximately $375 million. The transaction signals continued investor appetite for specialized software platforms that serve the life sciences sector, where computational tools have become increasingly central to reducing the time and cost of bringing new drugs to market.
Simulations Plus has carved out a distinctive niche by providing biosimulation software that helps drug developers predict how compounds will behave in the human body before costly clinical trials begin. That capability has grown in strategic importance as the pharmaceutical industry faces mounting pressure to improve research and development efficiency and reduce the rate of late-stage trial failures.
Read more Eli Lilly Expands Pain Pipeline With 4E Therapeutics Acquisition →
For Altaris, a healthcare-focused private equity firm, the acquisition fits a clear investment thesis: back software and data businesses that are deeply embedded in the workflows of large pharmaceutical and biotechnology companies. Such businesses tend to generate predictable, recurring revenue and benefit from high switching costs, making them attractive targets in any rate environment.
The deal also reflects broader consolidation trends in the biosimulation and regulatory science software market, where scale and data network effects are becoming competitive advantages. As regulators worldwide increasingly accept model-informed drug development as part of submission packages, platforms like those offered by Simulations Plus occupy a position that is both defensible and expanding.
Continue reading at SeekingAlpha
